Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
BioNexus Gene Lab Corp issued 392,329 shares of common stock of common stock to Fidelion for issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.
- Security
- common stock
- Shares
- 392,329 shares of common stock
- Purchaser
- Fidelion
- Consideration
- issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D
Exact text from the filing
d and outstanding equity of Fidelion. The issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder. Item 3.02 Unregistered Sales of Equity Securities. As described under Item 1.01 of this Current Report on Form 8-K,
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
BioNexus Gene Lab Corp issued 175,000 shares of common stock of common stock to ARC for consideration for ARC’s commitment under the Purchase Agreement.
- Security
- common stock
- Shares
- 175,000 shares of common stock
- Purchaser
- ARC
- Consideration
- consideration for ARC’s commitment under the Purchase Agreement
Exact text from the filing
the Company issued (i) 175,000 shares of common stock to ARC as consideration for ARC’s commitment under the Purchase Agreement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BioNexus Gene Lab Corp entered into ARC Group International Equity Purchase Agreement with ARC Group International Ltd. valued at up to $500,000,000 of common stock over 36 months (effective 2025-11-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- ARC Group International Ltd.
- Value
- up to $500,000,000 of common stock over 36 months
- Effective
- 2025-11-28
Exact text from the filing
. On November 28, 2025, the Company entered into two (2) material definitive agreements described herein below. A. ARC Group International Equity Purchase Agreement On November 28, 2025, BioNexus Gene Lab Corp. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with ARC Group International Ltd. (“ARC”), the parent of ARC Group Securities, a FINRA registered broker/dealer. Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share (“Common Stock”), over a 36-month period (the “Facility”).
View on SEC.gov